T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
1. A soluble T cell receptor (TCR) having the property of binding to SLLMWITQC (SEQ ID NO: 1) HLA-A*02 complex and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain, wherein
the alpha chain variable domain comprises an amino acid sequence that has at least 90% identity to SEQ ID NO: 12, and
the beta chain variable domain comprises an amino acid sequence that has at least 90% identity to SEQ ID NO: 15, and
the alpha chain variable domain sequence of amino acids residues 27-32 (CDR1), 50-57 (CDR2) and 91-107 (CDR3) and the beta chain variable domain sequence of amino acid residues 27-31 (CDR1), 49-55 (CDR2) and 93-106 (CDR3) are selected from one of the following:
a) alpha chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 41, 54 and 43, respectively, and beta chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 59, 60 and 61, respectively;
b) alpha chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 41, 54 and 43, respectively, and beta chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 59, 63 and 46, respectively;
c) alpha chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 41, 54 and 57, respectively, and beta chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 59, 60 and 61, respectively; or
d) alpha chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 41, 54 and 57, respectively, and beta chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 59, 63 and 46, respectively.
2. The TCR of claim 1 , wherein the alpha chain variable domain and the beta chain variable domain are selected from one of the following:
a) an alpha chain variable domain sequence provided in SEQ ID NO: 7 and a beta chain variable domain sequence provided in SEQ ID NO: 15;
b) an alpha chain variable domain sequence provided in SEQ ID NO: 7 and a beta chain variable domain sequence provided in SEQ ID NO: 18;
c) an alpha chain variable domain sequence provided in SEQ ID NO: 12 and a beta chain variable domain sequence provided in SEQ ID NO: 15; or
d) an alpha chain variable domain sequence provided in SEQ ID NO: 12 and a beta chain variable domain sequence provided in SEQ ID NO: 18.
3. The TCR of claim 1 , which is an alpha-beta heterodimer, wherein the TCR further comprises an alpha chain TRAC constant domain sequence and a beta chain TRBC1 or TRBC2 constant domain sequence, wherein, optionally, the alpha and beta chain constant domain sequences are modified by truncation or substitution to delete the native disulfide bond between Cys4 of exon 2 of TRAC and Cys2 of exon 2 of TRBC1 or TRBC2, or, wherein, optionally, the alpha and/or beta chain constant domain sequence(s) are modified by substitution of cysteine residues for Thr 48 of TRAC and Ser 57 of TRBC1 or TRBC2, the said cysteines forming a non-native disulfide bond between the alpha and beta constant domains of the TCR.
4. The TCR of claim 1 , which is in single chain format of the type Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, Vα-L-Vβ-Cβ, wherein Vα and Vβ are TCR α and β variable regions respectively, Cα and Cβ are TCR α and β constant regions respectively, and L is a linker sequence.
5. The TCR of claim 1 , associated with a detectable label, a therapeutic agent or a pharmacokinetics modifying moiety.
6. A TCR anti-CD3 fusion comprising the TCR of claim 1 , and an anti-CD3 antibody covalently linked to the C- or N-terminus of the alpha or beta chain of the TCR.
7. The TCR anti-CD3 fusion of claim 6 , comprising an alpha chain variable domain selected from SEQ ID NO: 7 and 12 and comprising a beta chain variable domain selected from SEQ ID NO: 15 and 18, wherein, optionally
the beta chain is linked to the anti-CD3 antibody sequence via a linker sequence, wherein, optionally, the linker sequence is selected from the group consisting of GGGGS (SEQ ID NO: 24), GGGSG (SEQ ID NO: 25), GGSGG (SEQ ID NO: 26), GSGGG (SEQ ID NO: 27), GSGGGP (SEQ ID NO: 28), GGEPS (SEQ ID NO: 29), GGEGGGP (SEQ ID NO: 30), and GGEGGGSEGGGS (SEQ ID NO: 31).
8. The TCR anti-CD3 fusion of claim 6 , comprising an alpha chain variable domain consisting of an amino acid sequence of SEQ ID NO: 12 and a beta chain variable domain consisting of an amino acid sequence of SEQ ID NO: 15 and wherein the beta chain is linked to an anti-CD3 antibody via a linker sequence.
9. The TCR anti-CD3 fusion of claim 6 , comprising an alpha chain variable domain consisting of an amino acid sequence of SEQ ID NO: 12 and a beta chain variable domain consisting of an amino acid sequence of SEQ ID NO: 15 and wherein the alpha chain is linked to an anti-CD3 antibody via a linker sequence.
10. A TCR anti-CD3 fusion according to claim 8 , wherein the alpha chain variable domain consists of the amino acid sequence of SEQ ID NO: 12 and the beta chain variable domain consists of the amino acid sequence of SEQ ID NO: 15 and wherein the beta chain is linked to an anti-CD3 antibody via the linker sequence of SEQ ID NO: 24.
11. A pharmaceutical composition comprising the soluble TCR of claim 1 , together with one or more pharmaceutically acceptable carriers or excipients.
12. The TCR of claim 1 , wherein the TCR binds to the SLLMWITQC (SEQ ID NO: 1) HLA-A*02 complex with an affinity greater than 50 μM.
13. The TCR anti-CD3 fusion of claim 6 , comprising an alpha chain consisting of SEQ ID NO: 37 and a beta chain consisting of SEQ ID NO: 38.
14. A TCR anti-CD3 fusion having the property of binding to SLLMWITQC (SEQ ID NO: 1) HLA-A*02 complex, wherein said TCR anti-CD3 fusion comprises an alpha chain amino acid sequence and a beta chain amino acid sequence pairing selected from the group consisting of:
a) an alpha chain amino acid sequence at least 90% identical to SEQ ID NO: 32 and a beta chain amino acid sequence at least 90% identical to SEQ ID NO: 33;
b) an alpha chain amino acid sequence at least 90% identical to SEQ ID NO: 35 and a beta chain amino acid sequence at least 90% identical to SEQ ID NO: 36;
c) an alpha chain amino acid sequence at least 90% identical to SEQ ID NO: 37 and a beta chain amino acid sequence at least 90% identical to SEQ ID NO: 38; or
d) an alpha chain amino acid sequence at least 90% identical to SEQ ID NO: 39 and a beta chain amino acid sequence at least 90% identical to SEQ ID NO: 40; and, wherein
the alpha chain variable domain sequence of amino acids residues 27-32 (CDR1), 50-57 (CDR2) and 91-107 (CDR3) and the beta chain variable domain sequence of amino acid residues 27-31 (CDR1), 49-55 (CDR2) and 93-106 (CDR3) are selected from one of the following:
(i) alpha chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 41, 54 and 43, respectively, and beta chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 59, 60 and 61, respectively;
(ii) alpha chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 41, 54 and 43, respectively, and beta chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 59, 63 and 46, respectively;
(iii) alpha chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 41, 54 and 57, respectively, and beta chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 59, 60 and 61, respectively; or
(iv) alpha chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 41, 54 and 57, respectively, and beta chain variable domain CDR1, CDR2 and CDR3 sequences provided in SEQ ID NOs: 59, 63 and 46, respectively.